The Diagnostic Value of MicroRNA-499 in Acute Myocardial Infarction: A systematic review and meta-analysis

Diagnostic Value of MicroRNA-499 in Acute Myocardial Infarction

  • Zhiyuan Zhang
  • Feifei Yan
  • Zichao Dong
  • Hong Du Department of Cardio Thoracic Surgery, No.988 Hospital of Joint Logistics Support Force
DOI: https://doi.org/10.5937/jomb0-52617
Keywords: MicroRNA-499, Acute Myocardial Infarction, Diagnostic Value, Meta-analysis

Abstract


Background: The objective of this study was to assess the diagnostic efficacy of MicroRNA-499 in cases of acute myocardial infarction.

Methods: On May 6, 2023, four electronic databases PubMed, Embase, Web of Science, and Cochrane Library were searched with no time restriction. Quality assessment was conducted using QUADAS-2. Random-effects meta-analysis was employed to combine sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The evaluation of publication bias was conducted through the utilization of Deeks' asymmetry test on the funnel plot.

Results: The studies that were included in the analysis, encompassing sample sizes ranging from 63 to 1155, exhibited a pooled sensitivity of 0.88 and a specificity of 0.97. The pooled positive likelihood ratio (PLR) was determined to be 29.78, while the negative likelihood ratio (NLR) was found to be 0.13. Furthermore, the pooled diagnostic odds ratio (DOR) was calculated to be 236.10. The area under the curve (AUC) was reported as 0.98.

Conclusions: MicroRNA-499 exhibits high sensitivity and specificity for diagnosing Acute Myocardial Infarction, indicating its potential as a valuable diagnostic biomarker.

References

1. Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet 2022; 399(10332): 1347-58.
2. Celik S, Giannitsis E, Wollert KC, Schwobel K, Lossnitzer D, Hilbel T, et al. Cardiac troponin T concentrations above the 99th percentile value as measured by a new high-sensitivity assay predict long-term prognosis in patients with acute coronary syndromes undergoing routine early invasive strategy. Clin Res Cardiol 2011; 100(12): 1077-85.
3. Li Y, Li L, Wang K, Wu P, Cui Y. Investigation on Risk Stratification and the Prognostic Value of hs-TnT Combined with MMP-2 in Patients with Acute Coronary Syndrome. Biomed Res Int 2021; 2021: 1040171.
4. Garcia-Padilla C, Lozano-Velasco E, Garcia-Lopez V, Aranega A, Franco D, Garcia-Martinez V, et al. Comparative Analysis of Non-Coding RNA Transcriptomics in Heart Failure. Biomedicines 2022; 10(12):
5. Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Bio 2020; 21(8): 475-90.
6. Deddens JC, Colijn JM, Oerlemans MI, Pasterkamp G, Chamuleau SA, Doevendans PA, et al. Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J Cardiovasc Transl 2013; 6(6): 884-98.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
8. Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem 2010; 56(7): 1183-5.
9. McInnes M, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. Jama-J Am Med Assoc 2018; 319(4): 388-96.
10. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155(8): 529-36.
11. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 3(6): 499-506.
12. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31(6): 659-66.
13. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 2012; 58(3): 559-67.
14. Li YQ, Zhang MF, Wen HY, Hu CL, Liu R, Wei HY, et al. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics 2013; 68(1): 75-80.
15. Devaux Y, Mueller M, Haaf P, Goretti E, Twerenbold R, Zangrando J, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med 2015; 277(2): 260-71.
16. Ji Q, Jiang Q, Yan W, Li X, Zhang Y, Meng P, et al. Expression of circulating microRNAs in patients with ST segment elevation acute myocardial infarction. Minerva Cardioangiol 2015; 63(5): 397-402.
17. Liu X, Fan Z, Zhao T, Cao W, Zhang L, Li H, et al. Plasma miR-1, miR-208, miR-499 as potential predictive biomarkers for acute myocardial infarction: An independent study of Han population. Exp Gerontol 2015; 72: 230-8.
18. Zhao CH, Cheng GC, He RL, Hong Y, Wan QL, Wang ZZ, et al. Analysis and clinical significance of microRNA-499 expression levels in serum of patients with acute myocardial infarction. Genet Mol Res 2015; 14(2): 4027-34.
19. Zhang L, Chen X, Su T, Li H, Huang Q, Wu D, et al. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J Thorac Dis 2015; 7(3): 303-8.
20. Shalaby SM, El-Shal AS, Shoukry A, Khedr MH, Abdelraheim N. Serum miRNA-499 and miRNA-210: A potential role in early diagnosis of acute coronary syndrome. Iubmb Life 2016; 68(8): 673-82.
21. Agiannitopoulos K, Pavlopoulou P, Tsamis K, Bampali K, Samara P, Nasioulas G, et al. Expression of miR-208b and miR-499 in Greek Patients with Acute Myocardial Infarction. In Vivo 2018; 32(2): 313-8.
22. Fawzy MS, Toraih EA, Hamed EO, Hussein MH, Ismail HM. Association of MIR-499a expression and seed region variant (rs3746444) with cardiovascular disease in Egyptian patients. Acta Cardiol 2018; 73(2): 131-40.
23. Liu G, Niu X, Meng X, Zhang Z. Sensitive miRNA markers for the detection and management of NSTEMI acute myocardial infarction patients. J Thorac Dis 2018; 10(6): 3206-15.
24. Gidlof O, Smith JG, Miyazu K, Gilje P, Spencer A, Blomquist S, et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. Bmc Cardiovasc Disor 2013; 13: 12.
25. Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C, et al. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris. Bmc Med Genomics 2013; 6: 16.
26. Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R, Santini G, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 2013; 167(2): 531-6.
27. Lee GK, Hsieh YP, Hsu SW, Lan SJ. Exploring diagnostic and prognostic predictive values of microRNAs for acute myocardial infarction: A PRISMA-compliant systematic review and meta-analysis. Medicine 2021; 100(29): e26627.
28. Wang K, Chen L, Liu L, Cui Y, Zhang X, Jiang J. The effects of atorvastatin on interventional therapy in patients with acute myocardial infarction. Minerva Med 2019; 110(2): 101-6.
29. Venugopal P, Balakrishnan K, Damal KS, George M. Usefullness of MicroRNAs in Predicting the Clinical Outcome of Patients with Acute Myocardial Infarction During Follow-Up: A Systematic Review. Genet Test Mol Bioma 2022; 26(5): 277-89.
30. Wang Q, Ma J, Jiang Z, Wu F, Ping J, Ming L. Identification of microRNAs as diagnostic biomarkers for acute myocardial infarction in Asian populations: A systematic review and meta-analysis. Medicine 2017; 96(24): e7173.
31. Xiao J, Shen B, Li J, Lv D, Zhao Y, Wang F, et al. Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. Int J Clin Exp Med 2014; 7(1): 136-41.
32. Wang J, Jia Z, Zhang C, Sun M, Wang W, Chen P, et al. miR-499 protects cardiomyocytes from H 2O 2-induced apoptosis via its effects on Pdcd4 and Pacs2. Rna Biol 2014; 11(4): 339-50.
Published
2024/11/20
Issue
Vol. 44 No. 2 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2024 Zhiyuan Zhang, Feifei Yan, Zichao Dong, Hong Du

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.